Expression, Activity, and Function of Phosphodiesterases in the Mature and Immature Ductus Arteriosus

A patent ductus arteriosus is due in large part to increased sensitivity of the premature ductus to PGE2. After PGE2 stimulation, cAMP concentrations are higher in the immature than in the mature ductus. cAMP concentrations depend on the rates of adenyl cyclase production and phosphodiesterase (PDE)-mediated degradation. We used ductus from immature (n = 25) and mature (n = 21) fetal sheep to investigate whether a developmental increase in PDE activity could explain the diminished cAMP accumulation that follows PGE2 stimulation in the mature ductus. With advancing gestation, mRNA expression of the smooth muscle PDE isoforms (PDE1A, 1B, 1C, 3A, 3B, 4D, and 5A) increased in the ductus as did their hydrolytic activities. Selective inhibitors of PDE1, PDE3, and PDE4 relaxed the mature and immature ductus in the presence of inhibitors of prostaglandin and nitric oxide production. The mature ductus required higher concentrations of each of the PDE inhibitors to inhibit its tension to the same extent as in the immature ductus. There were no developmental changes in PDE expression in the fetal aorta. In conclusion, we observed a developmental increase in cAMP and cGMP PDE activity that contributes to the decreased sensitivity of the late-gestation ductus arteriosus to vasodilators like PGE2.

[1]  F. Coceani,et al.  Interactions between NO, CO and an endothelium‐derived hyperpolarizing factor (EDHF) in maintaining patency of the ductus arteriosus in the mouse , 2007, British journal of pharmacology.

[2]  T. Nakanishi,et al.  In vivo Dilatation of the Postnatal Ductus Arteriosus by Atrial Natriuretic Peptide in the Rat , 2007, Neonatology.

[3]  T. Nakanishi,et al.  In vivo Dilatation of the Fetal and Postnatal Ductus Arteriosus by Inhibition of Phosphodiesterase 3 in Rats , 2006, Neonatology.

[4]  T. Nakanishi,et al.  In Vivo Dilation of Fetal and Neonatal Ductus Arteriosus by Inhibition of Phosphodiesterase-5 in Rats , 2005, Pediatric Research.

[5]  D. Ginzinger,et al.  Prostaglandin E2—Mediated Relaxation of the Ductus Arteriosus: Effects of Gestational Age on G Protein-Coupled Receptor Expression, Signaling, and Vasomotor Control , 2004, Circulation.

[6]  Hisham S. Elbatarny,et al.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. , 2003, Molecular pharmacology.

[7]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[8]  C. Ackerley,et al.  Cyclooxygenase‐1 and cyclooxygenase‐2 in the mouse ductus arteriosus: individual activity and functional coupling with nitric oxide synthase , 2003, British journal of pharmacology.

[9]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[10]  S. Archer,et al.  Sildenafil Reverses O2 Constriction of the Rabbit Ductus Arteriosus by Inhibiting Type 5 Phosphodiesterase and Activating BKCa Channels , 2002, Pediatric Research.

[11]  D. Tilley,et al.  Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. , 2002, Diabetes.

[12]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation , 2002, Circulation research.

[13]  C. Koch,et al.  Factors that increase the contractile tone of the ductus arteriosus also regulate its anatomic remodeling. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  G. Andelfinger,et al.  Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus. , 2001, American journal of physiology. Heart and circulatory physiology.

[15]  R. Kloner.  Cardiovascular risk and sildenafil. , 2000, The American journal of cardiology.

[16]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[17]  E. Degerman,et al.  Cyclic Nucleotide Phosphodiesterases (PDEs): Diverse Regulators of Cyclic Nucleotide Signals and Inviting Molecular Targets for Novel Therapeutic Agents , 1999, Thrombosis and Haemostasis.

[18]  R. Sharma,et al.  Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) , 1999, Cellular and Molecular Life Sciences CMLS.

[19]  C. Koch,et al.  Permanent Anatomic Closure of the Ductus Arteriosus in Newborn Baboons: The Roles of Postnatal Constriction, Hypoxia, and Gestation , 1999, Pediatric Research.

[20]  S. Black,et al.  Regulation of Ductus Arteriosus Patency by Nitric Oxide in Fetal Lambs: The Role of Gestation, Oxygen Tension, and Vasa Vasorum , 1998, Pediatric Research.

[21]  E. Krebs,et al.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. , 1997, The Journal of clinical investigation.

[22]  R. Marthan,et al.  Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications , 1997, Fundamental & clinical pharmacology.

[23]  M Hori,et al.  Calcium movements, distribution, and functions in smooth muscle. , 1997, Pharmacological reviews.

[24]  Toshio Kitazawa,et al.  Cyclic GMP Causes Ca2+ Desensitization in Vascular Smooth Muscle by Activating the Myosin Light Chain Phosphatase* , 1997, The Journal of Biological Chemistry.

[25]  W. K. Sonnenburg,et al.  19 Recent advances in the study of Ca2+/CaM-activated phosphodiesterases , 1997 .

[26]  C. Yan,et al.  Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions. , 1997, Advances in second messenger and phosphoprotein research.

[27]  J. Polson,et al.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.

[28]  J. Polson,et al.  Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. , 1994, Biochemical pharmacology.

[29]  G. Hassall,et al.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. , 1992, Biochemical pharmacology.

[30]  E. Degerman,et al.  Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. , 1989, Pharmacology & toxicology.

[31]  M. Heymann,et al.  Effect of gestational age on ductus arteriosus response to circulating prostaglandin E2. , 1983, The Journal of pediatrics.

[32]  M. Heymann,et al.  Age-dependent sensitivity of the lamb ductus arteriosus to indomethacin and prostaglandins. , 1980, The Journal of pediatrics.

[33]  M. Heymann,et al.  The developmental response of the ductus arteriosus to oxygen. , 1978, Biology of the neonate.